What is PDS Biotechnology Corporation (PDSB)?

PDS Biotechnology Corporation (PDSB) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of PDSB?

The current price of PDSB is $1.44. Prices are updated in real time on Stocks360.

What is PDSB's price-to-earnings (PE) ratio?

PDSB's trailing twelve-month PE ratio is -2.25, based on current price and earnings per share data available on Stocks360.

What is PDSB's market capitalization?

PDSB's market capitalization is $80,374,540.00, placing it in the small-cap tier.

PDS Biotechnology Corporation (PDSB)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.44

Market Cap

$80.37M

PE (TTM)

-2.25

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.45

Day Range

$1.35 – $1.55

52-wk Range

$0.20 – $1.79

Avg Volume

N/A

Volume

5.39M

PDS Biotechnology Corporation (PDSB) is a publicly traded company in the Healthcare sector. Latest price: $1.44. Market cap $80.37M. Trailing PE -2.25. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-31 · $0.94 2026-10-30 · $1.44 (+53.99%)

Earnings

Most Recent

Aug 13, 2026

EPS $-0.18 vs est. $-0.13

Missed by $0.05

Next Earnings

Nov 12, 2026

EPS estimate $-0.11

Proprietary Signals

Signal snapshot temporarily unavailable.

About PDS Biotechnology Corporation

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Healt…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.25×
P/S (TTM)	0.00×
P/B	-22.39×
P/FCF (TTM)	-4.79×
EV / EBITDA	-2.92×
EV / Sales	0.00×
Earnings Yield	-42.01%
Free Cash Flow Yield	-20.88%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$79.14M
Net Income (TTM)	-$33.77M
Free Cash Flow (TTM)	-$10.13M
Net Debt	-$1.23M
Working Capital	-$5.33M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-708.20%
Return on Invested Capital	-3550.39%